I would be happy with that also. There would be significant costs involved so it may be wise to seek a dual listing after the cosmeceutical lines are demonstrated to be profitable for more than a quarter or two. US investors would then have some tangible profit to think about although their markets do value highly prospective medical IP much more than the invisibility cloak of the ASX.
On midkine, a US listing would add commercial visibility and could align with the commencement of Australian based clinical stage trials. The higher market cap which would likely come via a US listing would fully cash in on the expected positive results of the clinical trials. One thing to remember is that the time line for kidney disease and cardiac trials will be much shorter than the timelines for comparable cancer trials.
cheers
CDY Price at posting:
22.5¢ Sentiment: None Disclosure: Held
